HK1008823A1 - Antibodies to mammalian interleukin-4 and peptides useful as antigens in their production - Google Patents

Antibodies to mammalian interleukin-4 and peptides useful as antigens in their production

Info

Publication number
HK1008823A1
HK1008823A1 HK98109519A HK98109519A HK1008823A1 HK 1008823 A1 HK1008823 A1 HK 1008823A1 HK 98109519 A HK98109519 A HK 98109519A HK 98109519 A HK98109519 A HK 98109519A HK 1008823 A1 HK1008823 A1 HK 1008823A1
Authority
HK
Hong Kong
Prior art keywords
antigens
antibodies
production
peptides useful
mammalian interleukin
Prior art date
Application number
HK98109519A
Inventor
Frank Lee
Takashi Yokota
Ken-Ichi Arai
Timothy Mosmann
Donna Rennick
Craig Smith
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/843,958 external-priority patent/US5552304A/en
Priority claimed from US06/908,215 external-priority patent/US5017691A/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1008823A1 publication Critical patent/HK1008823A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Antibodies to mammalian Interleukin-4 and muteins are provided, especially to native human IL-4s, as well as peptides useful as antigens in their production. Nucleic acids are disclosed which are capable of coding for the mammalian IL-4s and their muteins.
HK98109519A 1985-11-19 1998-07-29 Antibodies to mammalian interleukin-4 and peptides useful as antigens in their production HK1008823A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79966885A 1985-11-19 1985-11-19
US79966985A 1985-11-19 1985-11-19
US06/843,958 US5552304A (en) 1985-11-19 1986-03-25 CDNA Clones coding for human protein exhibiting a broad cellular activity spectrum (human interleukin-4)
US88155386A 1986-07-03 1986-07-03
US06/908,215 US5017691A (en) 1986-07-03 1986-09-17 Mammalian interleukin-4

Publications (1)

Publication Number Publication Date
HK1008823A1 true HK1008823A1 (en) 1999-05-21

Family

ID=27542219

Family Applications (2)

Application Number Title Priority Date Filing Date
HK98104741A HK1005594A1 (en) 1985-11-19 1998-06-02 Interleukin-4 protein having bcgf and tcgf activity on human cells (human interleukin-4)
HK98109519A HK1008823A1 (en) 1985-11-19 1998-07-29 Antibodies to mammalian interleukin-4 and peptides useful as antigens in their production

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK98104741A HK1005594A1 (en) 1985-11-19 1998-06-02 Interleukin-4 protein having bcgf and tcgf activity on human cells (human interleukin-4)

Country Status (23)

Country Link
EP (3) EP0249613B1 (en)
JP (2) JP2557361B2 (en)
KR (1) KR940007773B1 (en)
CN (1) CN1020472C (en)
AT (2) ATE198754T1 (en)
AU (1) AU610057B2 (en)
CZ (1) CZ414191A3 (en)
DE (2) DE3650751T2 (en)
DK (1) DK371087A (en)
ES (2) ES2153444T3 (en)
FI (1) FI102075B1 (en)
GR (1) GR3021198T3 (en)
HK (2) HK1005594A1 (en)
HU (1) HU208710B (en)
IE (1) IE80828B1 (en)
IL (1) IL80678A (en)
MY (1) MY101972A (en)
NO (1) NO301234B1 (en)
NZ (1) NZ218332A (en)
OA (1) OA08947A (en)
PT (1) PT83761B (en)
SK (1) SK414191A3 (en)
WO (1) WO1987002990A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0740943B2 (en) * 1985-09-30 1995-05-10 佑 本庶 DNA encoding novel polypeptide and method for producing the same
US5912136A (en) * 1985-11-19 1999-06-15 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5700915A (en) * 1985-11-19 1997-12-23 Schering Corporations Human interleukin immunopurification processes
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
EP0335900A4 (en) * 1986-12-19 1990-12-27 Immunex Corporation Human interleukin-4 muteins
SE8701004D0 (en) * 1987-03-11 1987-03-11 Astra Ab METHOD FOR THERAPY OF LEUKEMIAS AND CERTAIN OTHER MALIGNANCIES
EP0301835A1 (en) * 1987-07-29 1989-02-01 Schering Biotech Corporation Purification of human interleukin-4 expressed in Escherichia Coli
JPH02485A (en) * 1987-08-03 1990-01-05 Yuu Honshiyo Novel human interleukin-4, recombination vector for manifesting the same factor and transformant transformed by the same vector
EP0302429B1 (en) * 1987-08-03 1993-07-28 Tasuku Honjo Novel human interleukin 4, expression vectors for human interleukin 4 and transformants containing the same
HU211059B (en) * 1988-02-02 1995-10-30 Schering Biotech Corp Method for producing pharmaceutical compositions usable for reducing immunglobulin e responses, containing human il-4 antibodies
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB2218420B (en) * 1988-04-12 1992-07-15 British Bio Technology Synthetic gene encoding interleukin 4
EP0370090B1 (en) * 1988-05-13 1996-07-10 University Patents, Inc. Immunogens and biologically active peptides derived from shared sequences from antigens and anti-idiotypic antibodies or antibodies specific for cellular receptors of the antigens
US4958007A (en) * 1988-05-17 1990-09-18 Schering-Plough Corp. Extraction of human interleukin-4- from bacteria
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
WO1990006765A1 (en) * 1988-12-21 1990-06-28 Schering Corporation Use of interleukin-4 for lowering blood glucose levels and/or effecting weight reduction
US5236705A (en) * 1989-01-20 1993-08-17 The University Of Melbourne Fibrinolysis
US5077388A (en) * 1990-05-31 1991-12-31 Schering Corporation Purification of human interleukin-4 from a secreted escherichia coli mutant
AU635377B2 (en) * 1989-11-21 1993-03-18 University Of Melbourne, The Anti-inflammatory compositions and methods
SE465039B (en) * 1989-11-23 1991-07-15 Chemrec Ab MADE TO MAKE SUBSTANCES WITH HIGH SULFIDITY BEFORE SULFAT PREPARATION
US5188827A (en) * 1989-12-18 1993-02-23 Schering Corporation Use of interleukin-4- for lowering blood-cholesterol levels
CA2071908C (en) * 1989-12-20 2002-04-30 Lata Ramanathan Antibody antagonists of human interleukin-4
DE69116552T2 (en) * 1990-03-21 1996-05-30 Schering Corp USE OF IL-4 TO STRENGTHEN THE IMMUNE RESPONSE TO INFECTIOUS ANTIGEN CHALLENGES
EP0563254B1 (en) * 1990-12-19 1995-11-08 Schering Corporation Use of il-4 to enhance immune response to immunogens in vaccines
AU660959B2 (en) * 1991-01-10 1995-07-13 Schering Corporation Use of IL-4 to enhance the reparative phase of wound healing and repair and to enhance the healing of infected wounds and the wounds of diabetic mammals
US5494662A (en) * 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents
AUPN481295A0 (en) * 1995-08-16 1995-09-07 Medvet Science Pty. Ltd. Agonists of haemopoietic growth factors
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
ATE357516T1 (en) * 1998-05-12 2007-04-15 Isis Pharmaceuticals Inc MODULATION OF MOLECULAR INTERACTION POSITIONS IN RNA AND OTHER BIOMOLECULES
AUPQ005399A0 (en) * 1999-04-29 1999-05-27 Medvet Science Pty. Ltd. Agonists or antagonists for haemopoietic growth factors
ES2778053T3 (en) 2011-01-18 2020-08-07 Bioniz Llc Compositions to modulate gamma-c cytokine activity
CN102212888A (en) * 2011-03-17 2011-10-12 靳海峰 High throughput sequencing-based method for constructing immune group library
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
CN108350032A (en) 2015-10-09 2018-07-31 比奥尼斯有限责任公司 Adjust γ C- cytokine activities

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US799668A (en) * 1905-05-29 1905-09-19 Albert R Pritchard Dough kneader and mixer.
US799669A (en) * 1905-07-27 1905-09-19 Eugene S Regnier Combined cutting and raking implement.
US843958A (en) * 1905-11-20 1907-02-12 Whitehead & Hoag Co Key-ring tag.
US4613459A (en) * 1982-10-20 1986-09-23 Dana-Farber Cancer Institute Lymphocyte growth factor
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
WO1987004723A1 (en) * 1986-02-11 1987-08-13 Board Of Regents, The University Of Texas System Recombinant human b-cell growth factor
ZA872781B (en) * 1986-05-19 1987-10-05 Immunology Ventures B-cell stimulating factor
EP0335900A4 (en) * 1986-12-19 1990-12-27 Immunex Corporation Human interleukin-4 muteins

Also Published As

Publication number Publication date
EP0675136B1 (en) 2001-01-17
HK1005594A1 (en) 1999-01-15
DK371087D0 (en) 1987-07-16
NO301234B1 (en) 1997-09-29
AU610057B2 (en) 1991-05-16
JP2568394B2 (en) 1997-01-08
NO872988D0 (en) 1987-07-17
DE3650751D1 (en) 2001-02-22
KR940007773B1 (en) 1994-08-25
EP0249613A1 (en) 1987-12-23
JPS63501401A (en) 1988-06-02
HUT43630A (en) 1987-11-30
IE863042L (en) 1987-05-19
JP2557361B2 (en) 1996-11-27
FI102075B (en) 1998-10-15
OA08947A (en) 1990-11-30
EP0230107A1 (en) 1987-07-29
PT83761A (en) 1986-12-01
CN86108579A (en) 1988-01-27
DK371087A (en) 1987-09-21
SK414191A3 (en) 1995-07-11
FI102075B1 (en) 1998-10-15
IL80678A (en) 1999-05-09
GR3021198T3 (en) 1996-12-31
JPH0884591A (en) 1996-04-02
FI873141A0 (en) 1987-07-16
MY101972A (en) 1992-02-29
ATE198754T1 (en) 2001-02-15
ES2153444T3 (en) 2001-03-01
EP0249613B1 (en) 1996-07-03
CZ414191A3 (en) 1993-04-14
AU6733487A (en) 1987-06-02
EP0675136A3 (en) 1996-03-13
DE3650538T2 (en) 1996-12-12
EP0675136A2 (en) 1995-10-04
FI873141A (en) 1987-07-16
CN1020472C (en) 1993-05-05
WO1987002990A1 (en) 1987-05-21
IE80828B1 (en) 1999-03-10
DE3650751T2 (en) 2001-08-02
ES2088858T3 (en) 1996-10-01
NO872988L (en) 1987-09-18
IL80678A0 (en) 1987-02-27
PT83761B (en) 1989-06-30
NZ218332A (en) 1993-04-28
HU208710B (en) 1993-12-28
DE3650538D1 (en) 1996-08-08
ATE140009T1 (en) 1996-07-15

Similar Documents

Publication Publication Date Title
OA08947A (en) Mammalian interleukin-4.
PH25120A (en) Replicable expression vehicle and process of preparation thereof
EP0293443A4 (en) Construction of synthetic dna and its use in large polypeptide synthesis.
MX26714A (en) PROCESS FOR THE PREPARATION OF ALBUM OF VECTOR HUMAN SERUM AND PLASMIDE USED AS WELL AS METHYLOTROPHIC YEAST TRANSFORMED OBTAINED
IL81018A (en) Fusion proteins comprising small fragments of human interleukin-2 as ballast,process for its preparation and genes,vectors and transformed host containing said fragments and used in the process
HUT44615A (en) Process for preparing gm-cst protein and its derivatives

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20061118